Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Tiotropium (18mcg) in Chronic Obstructive Pulmonary Disease (COPD) Patients With a Respiratory Infection

This study has been completed.
Information provided by (Responsible Party):
Boehringer Ingelheim Identifier:
First received: November 30, 2011
Last updated: June 3, 2014
Last verified: March 2014
The aim of the study is to investigate whether the early introduction of maintenance bronchodilator therapy during an acute symptomatic episode of the disease shows benefits on the recovery of symptoms. It also represents an opportunity to identify COPD patients earlier in their disease state and start maintenance therapy, if appropriate.

Condition Intervention Phase
Pulmonary Disease, Chronic Obstructive
Drug: tiotropium
Drug: Placebo
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A 12-week, Randomised, Placebo-controlled, Double-blind, Parallel Group, Multi-center Trial to Assess the Efficacy and Safety of Tiotropium Bromide (18 µg) Delivered Via the HandiHaler® in Patients With Newly Diagnosed and/or Maintenance Treatment naïve Chronic Obstructive Pulmonary Disease (COPD) Experiencing an Acute Respiratory Infection (TICARI 1: Tiotropium In COPD Patients With an Acute Respiratory Infection 1)

Resource links provided by NLM:

Further study details as provided by Boehringer Ingelheim:

Primary Outcome Measures:
  • Trough FEV1 After 12 Weeks on Study Drug [ Time Frame: 12 weeks ]
    The primary endpoint was trough forced expiratory volume in 1 second (FEV1) after 12 weeks on study drug. Trough forced expiratory volume in 1 second (FEV1)was defined as the FEV1 measurement prior to the next dosing of study drug and approximately 24 hours after the last inhalation of study drug.

Secondary Outcome Measures:
  • Time to Recovery From Acute Respiratory Symptoms [ Time Frame: 12 weeks ]

    Time to recovery was assessed with the EXACT-PRO questionnaire tool. The EXACT-PRO was designed to collect data to quantify frequency, severity, and duration of exacerbations in patients with COPD including the onset of and the recovery from COPD exacerbations.

    The EXACT-PRO is a 14-item questionnaire. Each attribute or item was assessed on a five- or six-point ordinal scale and summed to yield a total score that was converted to a 0-100 scale, with higher scores indicating a more severe health state or exacerbation.

    The EXACT-PRO was answered by the patients on a daily basis in the evening.

  • Trough FVC (in Litres) at 12 Weeks [ Time Frame: 12 weeks ]
    The trough Forced Vital Capacity (FVC) was defined as the FVC measurement prior to the next dosing of study drug and approximately 24 hours after the last inhalation of study drug.

  • Responder Status at Week 4 Clinic Visit [ Time Frame: 4 weeks ]

    Responder status was determined at each clinic visit. The number and percentage of subjects in each of the following 3 classes were presented:

    • Subject recovered without change of therapy (subjects who received an additional course of antibiotics and/or systemic corticosteroids starting after Visit 1 were not included).
    • Subject recovered but had a change in therapy (subject received an additional course of antibiotics and/or systemic corticosteroids starting after Visit 1).
    • Subject did not recover.

  • Responder Status at Week 12 Clinic Visit [ Time Frame: 12 weeks ]

    Responder status was determined at each clinic visit. The number and percentage of subjects in each of the following 3 classes were presented:

    • Subject recovered without change of therapy (subjects who received an additional course of antibiotics and/or systemic corticosteroids starting after Visit 1 were not included).
    • Subject recovered but had a change in therapy (subject received an additional course of antibiotics and/or systemic corticosteroids starting after Visit 1).
    • Subject did not recover.

  • Weekly Rescue Medication Use Over the 12 Weeks of Study [ Time Frame: 12 weeks ]
    Daily rescue albuterol use was recorded in the diary in response to the following question: How many puffs of rescue medication did you use during the last 24 hours? The weekly rescue medication use was derived by summing the daily uses over the 12 weeks and dividing this total by 12 weeks.

Enrollment: 140
Study Start Date: November 2011
Study Completion Date: December 2012
Primary Completion Date: December 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: tiotropium 18mcg
Drug: tiotropium
Placebo Comparator: Placebo
Drug: Placebo


Ages Eligible for Study:   40 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion criteria:

  1. All patients must sign an informed consent consistent with International Conference on Harmonization - Good Clinical Practice (ICH-GCP) guidelines prior to participation in the trial and conducting any study procedures.
  2. Male or female patients 40 years of age or older.
  3. Ability to independently read and understand English and/or Spanish.
  4. Any self-reported history of smoking (e.g. = 100 cigarettes (~5 packs) during life-time).
  5. Acute respiratory symptoms for up to 7 days
  6. All patients must have a diagnosis of COPD, and must have an airway obstruction with a post-bronchodilator (Forced Expiratory Volume in 1 second (FEV1)/Forced Vital Capacity (FVC)) <0.7. The diagnosis of COPD can be made at Visit 1.
  7. The clinical assessment of the enrolled patient in the judgement of the investigator supports the introduction of COPD maintenance therapy.
  8. Patients must be able to inhale medication in a competent manner from the HandiHaler® device and from a metered dose inhaler (MDI)

Exclusion criteria:

  1. Therapy with any long-acting bronchodilator, short-acting anticholinergic, inhaled corticosteroid or regular maintenance use (>14 consecutive days) of systemic corticosteroid (the latter for respiratory indications) during the previous 6 months (short course of systemic corticosteroid for up to 14 days for respiratory indications allowed); in case of use of systemic corticosteroid medication for other than respiratory conditions, then exclusion of unstable doses (i.e., less than six weeks on stable dose) or at doses in excess of the equivalent of 10 mg prednisolone-equivalent per day. In addition, daily use of short-acting beta2-agonist for more than a week prior to Visit 0 not allowed.

    The following exclusion criteria apply at Visit 1:

  2. Significant diseases other than COPD. A significant disease is defined as a disease or condition which, in the opinion of the investigator, may put the patient at risk because of participation in the study or may influence the patient¿s ability to participate in the study.
  3. A recent history (i.e., six months or less) of myocardial infarction. Patients being stable with a history of cardiac stents prior to six month are permitted.
  4. Any unstable or life-threatening cardiac arrhythmia requiring intervention or change in drug therapy during the last year.
  5. Hospitalisation for cardiac failure (New York Heart Association (NYHA) Class III or IV) during the past year.
  6. Any significant or new ECG findings at V1 as judged by the investigator, including, but not limited to signs of ischemia, arrhythmia, heart failure, or the report of chest pain.
  7. Known active tuberculosis.
  8. Current asthma (patient treated for asthma in the last 2 years), cystic fibrosis, clinical diagnosis of bronchiectasis, interstitial lung disease, or pulmonary thromboembolic disease.
  9. A history of thoracotomy with pulmonary resection. Patients with a history of thoracotomy for other reasons should be evaluated as per exclusion criterion no. 2.
  10. Malignancy for which the patient has undergone resection, radiation, chemotherapy or biological treatments within the last year or is currently on active radiation therapy, chemotherapy or biological treatment. Patients with treated basal cell carcinoma are allowed.
  11. At visit 0 or 1, a severe respiratory infection, e.g. pneumonia (as suspected by investigator), any condition or exacerbation requiring ER visit or hospitalization, need for oxygen treatment.
  12. Known hypersensitivity to anticholinergic drugs, lactose, or any other components of the HandiHaler® or MDI inhalation solution delivery system.
  13. Treatment with any restricted pulmonary medication
  14. Requirement of supplemental oxygen therapy for = 24 hours during the previous 6 months.
  15. Known moderate to severe renal impairment.
  16. Known narrow angle glaucoma.
  17. Significant symptomatic prostatic hyperplasia or bladder-neck obstruction. Patients whose symptoms are controlled on treatment may be included.
  18. Pregnant or nursing women or women of childbearing potential not using a medically approved means of contraception (i.e., oral contraceptives, intrauterine devices, diaphragm or subdermal implants e.g., Norplant®) for at least three months prior to and for the duration of the trial.
  19. Significant alcohol or drug abuse within the past 12 months.
  20. Actively participating in a pulmonary rehabilitation program.
  21. Previously randomized in this study or currently participating in another interventional study.
  22. Visual impairment that as judged by the investigator does not allow the patient to independently read and complete the questionnaires and electronic diary (eDiary).
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01483625

  Hide Study Locations
United States, Arizona
205.479.01017 Boehringer Ingelheim Investigational Site
Tucson, Arizona, United States
United States, California
205.479.01036 Boehringer Ingelheim Investigational Site
Riverside, California, United States
205.479.01024 Boehringer Ingelheim Investigational Site
San Diego, California, United States
United States, Florida
205.479.01043 Boehringer Ingelheim Investigational Site
DeLand, Florida, United States
205.479.01040 Boehringer Ingelheim Investigational Site
St. Petersburg, Florida, United States
United States, Michigan
205.479.01022 Boehringer Ingelheim Investigational Site
Chelsea, Michigan, United States
United States, Mississippi
205.479.01041 Boehringer Ingelheim Investigational Site
Picayune, Mississippi, United States
United States, Missouri
205.479.01037 Boehringer Ingelheim Investigational Site
St. Louis, Missouri, United States
United States, North Carolina
205.479.01005 Boehringer Ingelheim Investigational Site
Tabor City, North Carolina, United States
205.479.01008 Boehringer Ingelheim Investigational Site
Wilmington, North Carolina, United States
United States, Ohio
205.479.01003 Boehringer Ingelheim Investigational Site
Cincinnati, Ohio, United States
United States, Pennsylvania
205.479.01002 Boehringer Ingelheim Investigational Site
Pittsburgh, Pennsylvania, United States
205.479.01044 Boehringer Ingelheim Investigational Site
Tipton, Pennsylvania, United States
United States, South Carolina
205.479.01006 Boehringer Ingelheim Investigational Site
Charleston, South Carolina, United States
205.479.01001 Boehringer Ingelheim Investigational Site
Columbia, South Carolina, United States
205.479.01007 Boehringer Ingelheim Investigational Site
Easley, South Carolina, United States
205.479.01026 Boehringer Ingelheim Investigational Site
Fort Mill, South Carolina, United States
205.479.01031 Boehringer Ingelheim Investigational Site
Gaffney, South Carolina, United States
205.479.01012 Boehringer Ingelheim Investigational Site
Greenville, South Carolina, United States
205.479.01048 Boehringer Ingelheim Investigational Site
Hodges, South Carolina, United States
205.479.01004 Boehringer Ingelheim Investigational Site
Spartanburg, South Carolina, United States
205.479.01019 Boehringer Ingelheim Investigational Site
Union, South Carolina, United States
United States, South Dakota
205.479.01039 Boehringer Ingelheim Investigational Site
Rapid City, South Dakota, United States
United States, Tennessee
205.479.01033 Boehringer Ingelheim Investigational Site
Chattanooga, Tennessee, United States
United States, Texas
205.479.01028 Boehringer Ingelheim Investigational Site
Killeen, Texas, United States
United States, Virginia
205.479.01038 Boehringer Ingelheim Investigational Site
Ettrick, Virginia, United States
205.479.01047 Boehringer Ingelheim Investigational Site
Norfolk, Virginia, United States
Sponsors and Collaborators
Boehringer Ingelheim
Study Chair: Boehringer Ingelheim Boehringer Ingelheim
  More Information

Responsible Party: Boehringer Ingelheim Identifier: NCT01483625     History of Changes
Other Study ID Numbers: 205.479
Study First Received: November 30, 2011
Results First Received: December 23, 2013
Last Updated: June 3, 2014

Additional relevant MeSH terms:
Lung Diseases
Lung Diseases, Obstructive
Pulmonary Disease, Chronic Obstructive
Chronic Disease
Respiratory Tract Infections
Respiratory Tract Diseases
Disease Attributes
Pathologic Processes
Tiotropium Bromide
Bronchodilator Agents
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Asthmatic Agents
Respiratory System Agents
Cholinergic Antagonists
Cholinergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action processed this record on April 28, 2017